Ceftazidime

Ceftazidime
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Ceftazidime is a cephalosporin that is FDA approved for the treatment of bacterial infections of gram negative, gram positive aerobic bacterias and for anaerobic bacterias. Common adverse reactions include diarrhea.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Lower Respiratory Tract Infections

Pneumonia: caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp; Proteus mirabilis; Escherichia coli; Serratia spp; Citrobacter spp; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains).

Skin and Skin-Structure Infections

Caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci).

Urinary Tract Infections

Both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli.

Bacterial Septicemia

Caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains).

Bone and Joint Infections

Caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains).

Gynecologic Infections

Including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli.

Intra-abdominal Infections

Including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp (many strains of Bacteroides fragilis are resistant).

Central Nervous System Infections

Including meningitis, caused] by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae.

The usual adult dosage is 1 gram administered intravenously every 8 to 12 hours. The dosage should be determined by the susceptibility of the causative organisms, the severity of infection, and the condition and renal function of the patient.

The guidelines for dosage of ceftazidime for injection are listed in the following table. The following dosage schedule is recommended:

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ceftazidime in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ceftazidime in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ceftazidime in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ceftazidime in pediatric patients.

Contraindications

There is limited information regarding Ceftazidime Contraindications in the drug label.

Warnings

There is limited information regarding Ceftazidime Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Ceftazidime Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Ceftazidime Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Ceftazidime Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Ceftazidime in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ceftazidime in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Ceftazidime during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Ceftazidime in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Ceftazidime in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Ceftazidime in geriatric settings.

Gender

There is no FDA guidance on the use of Ceftazidime with respect to specific gender populations.

Race

There is no FDA guidance on the use of Ceftazidime with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Ceftazidime in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Ceftazidime in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Ceftazidime in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Ceftazidime in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Ceftazidime Administration in the drug label.

Monitoring

There is limited information regarding Ceftazidime Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Ceftazidime and IV administrations.

Overdosage

There is limited information regarding Ceftazidime overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Ceftazidime Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Ceftazidime Mechanism of Action in the drug label.

Structure

There is limited information regarding Ceftazidime Structure in the drug label.

Pharmacodynamics

There is limited information regarding Ceftazidime Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Ceftazidime Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Ceftazidime Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Ceftazidime Clinical Studies in the drug label.

How Supplied

There is limited information regarding Ceftazidime How Supplied in the drug label.

Storage

There is limited information regarding Ceftazidime Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Ceftazidime |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Ceftazidime |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Ceftazidime Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Ceftazidime interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Ceftazidime Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Ceftazidime Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Ceftazidime
FORATZ®,TAZICEF®,CEFTAZIDIME® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
Compatibility and stability
Directions for use
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]

Overview

Ceftazidime (INN) (IPA: Template:IPA) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram-positive and Gram-negativebacteria. Unlike most third-generation agents, it is active against Pseudomonas aeruginosa, however it has weaker activity against Gram-positive microorganisms and is not used for such infections.

Category

Cephalosporin, Third-Generation

US Brand Names

FORTAZ^®, TAZICEF^®, CEFTAZIDIME^®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | Compatibility and Stability | Directions For Use | How Supplied | Labels and Packages

References

http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050578s053,050634s020lbl.pdf